SYDNEY (Reuters) - The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh ...
ZURICH (Reuters) - COVID-19 vaccine maker Moderna does not expect any problems in developing a booster shot to protect against the Omicron variant of the coronavirus and could begin work in a few ...
Moderna Inc. on Tuesday reported "positive interim results" from a late-stage trial of what it calls the "next-generation ...
HONG KONG/ SYDNEY--Drugmaker Moderna's CEO set off fresh alarm bells in financial markets on Tuesday after he warned that COVID-19 vaccines were unlikely to be as effective against the Omicron ...
Moderna said its Covid vaccine would likely experience a 'material drop' in efficacy against Omicron, while Regeneron ... with London's Financial Times, CEO Stephane Bancel said the existing ...
In the trial, mRNA-1283 elicited a higher immune response against the SARS-CoV-2 virus, compared to mRNA-1273.222.
Moderna shares rose Wednesday after it said that it had received up to $750 million from Blackstone Life Sciences to advance its flu program.
Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life ...
Moderna is focusing on advancing its mRNA vaccine pipeline for other viruses following a decline in COVID-19 product sales.
Moderna CEO Stéphane Bancel explains how technology ... final approval to updated COVID-19 vaccines targeting the dominant omicron variant on Thursday. According to the White House's COVID ...
Moderna CEO Stéphane Bancel anticipated that “given the need for a COVID-19 vaccine in infants and young children, we are working with the US FDA and regulators around the world to send these ...